Guidance and navigation control proteins and method of making and using thereof

US12384850B2 · kind B2 · utility

Assignee

• SystImmune, Inc. · US

Inventors

• Yi Zhu · Chengdu, CN
• Ole Olsen · Everett, US
• Dong Xia · Redmond, US
• David Jellyman · Duvall, US
• Katrina Bykova · Seattle, US
• Anne-Marie K. Rousseau · Seattle, US
• Bill Brady · Watertown, US
• Blair R. Renshaw · Renton, US
• Brian R. Kovacevich · Snohomish, US
• Yu Liang · Tokyo, JP
• Camilla Wang · Sammamish, US
• Zeren Gao · Redmond, US

Key dates

• Filing date: Jun 22, 2018
• Grant date: Aug 12, 2025
• Expiry date: Jul 25, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The application provides guidance and navigation control (GNC) proteins. In one embodiment, the GNC protein Comprises a T-cell binding moiety and a cancer-targeting moiety, wherein the T-cell binding moiety has a binding specificity to a T-cell receptor comprising CD3, CD28, PDL1, PD1, OX40, 4-1BB, GITR, TIGIT, TIM-3, LAG-3, CTLA4, CD40, VISTA, ICOS, BTLA, Light, NKp30, CD28H, CD27, CD226, CD96, CD112R, A2AR, CD160, CD244, CECAM1, CD200R, TNFRSF25 (DR3), or a combination thereof, and wherein the cancer targeting moiety has a binding specificity to a cancer cell receptor.